Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intracameral Moxifloxacin for Endophthalmitis Prevention
NCT02770729Phase 3Terminated
- Sponsor
- Universidade Estadual de Campinas
- Start
- Jan 2017
- Primary completion
- Feb 2018
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of moxifloxacin in endophthalmitis (2 arms), sponsored by Universidade Estadual de Campinas. Primary endpoint: Incidence of Acute Endophthalmitis at 45 days. Started Jan 2017; status: terminated.
02
Drugs
moxifloxacin
03
Conditions
endophthalmitis
Beyond the preview
Go deeper on NCT02770729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02770729.